Search Results

You are looking at 121 - 130 of 154 items for :

  • "genetic counseling" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

The Role of Radiation Therapy in the Treatment of Medullary Thyroid Cancer

Stephanie A. Terezakis and Nancy Y. Lee

the presence of MTC. Because MTC has high penetrance in all 3 familial forms, first-degree relatives of a family member with the mutation should receive genetic counseling and testing if the patient index demonstrates the RET mutation. 10 , 11 The

Full access

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

and is not required. Genetic counseling is recommended if the patient is considered to be at high risk for hereditary breast cancer as defined by the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian (available at NCCN

Full access

Understanding Causes of Inferior Outcomes in Adolescents and Young Adults With Cancer

Julie A. Wolfson, Kelly M. Kenzik, Blake Foxworthy, John M. Salsman, Katherine Donahue, Marie Nelson, Mary Beth Littrell, Grant R. Williams, and Jennifer M. Levine

Pediatric Oncology and Hematology . Am J Med Genet A 2017 ; 173 : 1017 – 1037 . 44. Morand M , Roth M , Peterson SK , Factors impacting adolescent and young adult cancer patients’ decision to pursue genetic counseling and testing

Full access

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

tumor MSI-H or dMMR is identified, the panel recommends referral to genetic counseling for consideration of germline testing for Lynch syndrome. New Systemic Therapy Options for CRPC PARP Inhibitors for Patients With DNA Repair Gene Mutations Results of

Full access

Abstracts From the NCCN 2024 Annual Conference

genetic testing were identified through the Ambry CARE Program and were offered pre-test education and a 36-gene panel test. Patients testing positive for a pathogenic or likely pathogenic (P/LP) variant were offered third-party genetic counseling. A

Full access

Part 2: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™

18% were referred to genetic counseling. Results are presented in Table 1 . Conclusions: The Athena model effectively identifies women previously unaware of their elevated breast cancer risk status. The findings support the value and efficiency of

Full access

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

reporting the pathologic analysis of all breast cancer specimens. Genetic Counseling: Genetic counselling is recommended for patients considered to be at high risk for hereditary breast cancer as defined by the NCCN Guidelines for Genetic/Familial High

Full access

Breast Cancer Version 2.2015

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

.cap.org ). The NCCN Breast Cancer Panel endorses the use of the CAP protocols for reporting the pathologic analysis of all breast cancer specimens. Genetic Counseling For patients considered to be at high risk for hereditary breast cancer as defined by

Full access

Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

promoter methylation to assess for an epigenetic process rather than a germline mutation. 16 Genetic counseling and testing is recommended for patients with all other MMR abnormalities and for patients without MMR defects but who have a significant family

Full access

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Amar Gajjar, Anita Mahajan, Mohamed Abdelbaki, Clarke Anderson, Reuben Antony, Tejus Bale, Ranjit Bindra, Daniel C. Bowers, Kenneth Cohen, Bonnie Cole, Kathleen Dorris, Ralph Ermoian, Andrea Franson, Jeffrey Helgager, Daniel Landi, Chi Lin, Laura Metrock, Ronica Nanda, Joshua Palmer, Sonia Partap, Ashley Plant, Sumit Pruthi, Renee Reynolds, Paul Ruggieri, Duncan Stearns, Phillip Storm, Anthony Wang, Katherine Warren, Nicholas Whipple, Wafik Zaky, Nicole R. McMillian, and Lenora A. Pluchino

adjuvant therapy, pediatric diffuse high-grade gliomas typically have a poor prognosis. Referral for cancer predisposition evaluation and/or genetic counseling should be considered. Principles of Brain and Spine Tumor Imaging Conventional MRI is